Atnaa Atropine And Pralidoxime Chloride Kit
NDC Package 11704-777-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Atnaa Atropine And Pralidoxime Chloride (atropine and pralidoxime chloride) kits is the ATNAA is indicated for the treatment of poisoning by susceptible organophosphorous nerve agents having anticholinesterase activity. This formulation utilizes a kit delivery system. Marketed by Meridian Medical Technologies, Llc, this product is identified by NDC 11704-777 and is authorized under FDA application NDA021175.

Identification & Billing

NDC Package Code
11704-777-01
Package Description
1 KIT in 1 CARTON * .7 mL in 1 SYRINGE, GLASS * 2 mL in 1 SYRINGE, GLASS
Product Code
11704-777
11-Digit Billing Format
11704077701
RxNorm Crosswalk
  • RxCUI: 727415 - atropine 2.1 MG / pralidoxime Cl 600 MG Auto-Injector
  • RxCUI: 727415 - 2.7 ML atropine 0.778 MG/ML / pralidoxime chloride 222 MG/ML Auto-Injector
  • RxCUI: 727415 - atropine 2.1 MG / pralidoxime chloride 600 MG Auto-Injector

Clinical Specifications

Proprietary Name
Atnaa Atropine And Pralidoxime Chloride Auto-injector
Non-Proprietary Name
Atropine And Pralidoxime Chloride
Dosage Form
Kit - A packaged collection of related material.
Administration Route
Intramuscular - Administration within a muscle.
Usage Information
The ATNAA is indicated for the treatment of poisoning by susceptible organophosphorous nerve agents having anticholinesterase activity.

Regulatory & Marketing

Labeler Name
Meridian Medical Technologies, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021175
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-17-2002
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11704-777-01 identifies a specific commercial package of 1 kit in 1 carton * .7 ml in 1 syringe, glass * 2 ml in 1 syringe, glass of Atnaa Atropine And Pralidoxime Chloride Auto-injector, a human prescription drug labeled by Meridian Medical Technologies, Llc. This kit is formulated for intramuscular use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Meridian Medical Technologies, Llc on January 17, 2002. The current certification is valid through December 31, 2026.

How is this Meridian Medical Technologies, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11704077701. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
11704-777-01
11-Digit CMS (5-4-2)
11704-0777-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.